Article
“Endothelial antibody factory” at the Blood Brain Barrier: novel approach to therapy of neurodegenerative diseases
2022-03-01
Abstract excerpt
<title>Abstract</title> <p>Phase III clinical trials of immunotherapies against Alzheimer’s disease have failed to hit major endpoints. Despite the high doses administered, small fractions of injected monoclonal antibodies cross the blood brain barrier (BBB), likely resulting in an antibody concentration in the brain parenchyma that is too low for a therapeutic effect. Here we report a novel approach to circumven...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7bca38d5-c33b-554c-bbcc-f301333264ae
- DOI
- 10.21203/rs.3.rs-1325519/v1
